Our Promise is our north star for ourselves, patients, and society. It builds upon our history of forging life-altering scientific breakthroughs and reminds us that we are on a bolder quest than ever before - to be courageous changemakers in solving the world’s most complex health challenges and improving the lives of all patients. http://spr.ly/6049V62k7
About us
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or patientinfo@gene.com. Community Guidelines: 1. We want to foster positive conversation and diverse community around the issues we are passionate about. To that end, we remove profanity, content that contains credible threats or hate speech, content that is aimed at private individuals, personal information meant to harass someone, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
- Website
-
http://www.gene.com
External link for Genentech
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Founded
- 1976
- Specialties
- Oncology, Immunology, Disorders of Tissue Growth and Repair, Neuroscience and Infectious Disease, Metabolism, and Ophthalmology
Locations
-
Primary
1 Dna Way
South San Francisco, California 94080, US
-
1000 New Horizons Way
Vacaville, California 95688, US
-
1 Antibody Way
Oceanside, California 92056, US
-
4625 NE Brookwood Pkwy
Hillsboro, Oregon 97124, US
Employees at Genentech
Updates
-
New two-year data about the efficacy and safety of our unique therapeutic approach that may provide diabetic macular edema (DME) and diabetic retinopathy (DR) patients with an alternative to regular eye injections were presented at this year's ASRS – American Society of Retina Specialists meeting. Learn more about these results and our commitment to helping people with diabetic eye diseases prevent #VisionLoss: http://spr.ly/6045iljDR #EyeHealth
-
At #ASRS2024, we presented data on our treatments for the leading causes of blindness, including diabetic macular edema (DME). Levi Garraway, our Chief Medical Officer and Head of Global Product Development, highlights our work to address #VisionLoss. Learn more here: http://spr.ly/6046iw0Tr
ASRS 2024: Levi Garraway, M.D., PH.D
-
New long-term data from the RHONE-X trial of DME patients treated with our bispecific antibody showed sustained and robust retinal drying and vision improvements. Learn more about these results, which were presented at this year’s #ASRS2O24, and how we are continuing to advance science for people living with #DiabeticEyeDisease: http://spr.ly/6043iguA9
-
We are continuously researching and developing treatment approaches that push past current boundaries for retinal conditions. Our recent innovations are a testament to our commitment to helping the retina community address conditions that cause blindness. Learn more about our innovations for wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion: http://spr.ly/60499Ymr1
-
Congratulations to our own Aviv Regev, Head of Genentech Research and Early Development, for being elected both as The Royal Society (UK) Foreign Member and an EMBO Associate Member this year. Both of these recognitions honor scientists who have made outstanding contributions to science and are leaders in their fields.
-
-
Today, we reintroduced a first-of-its-kind therapeutic approach that provides an alternative to standard of care eye injections for wet age-related macular degeneration, a leading cause of blindness for people aged 60 and over in the U.S. This evolution of the Port Delivery Platform lays the foundation for future retinal advancements. Read the full announcement here: http://spr.ly/60449Y8DE
Genentech: Press Releases | Monday, Jul 8, 2024
gene.com
-
The FDA approved the prefilled syringe version of our medicine to treat wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion. Together, these three retinal conditions affect around 3 million people in the U.S. and are among the leading causes of vision loss. The prefilled syringe is designed to provide retina specialists a ready-to-use option for simpler administration. Learn more: http://spr.ly/60489pado
Genentech: Press Releases | Thursday, Jul 4, 2024
gene.com
-
We had another amazing year celebrating the LGBTQ+ community at the San Francisco Pride Parade! This weekend, hundreds of our employees, led by our employee resource group gPRIDE, came together to connect, spread joy and uplift LGBTQ+ people within our community and beyond. Check out some of our favorite moments from the parade and our float. #PrideMonth #SFPRIDE54
-